CLINICAL TRIALS PROFILE FOR ASPIRIN; OMEPRAZOLE
✉ Email this page to a colleague
All Clinical Trials for Aspirin; Omeprazole
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00349661 ↗ | Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel | Completed | University Hospital, Brest | Phase 3 | 2006-06-01 | Objectives: A prospective investigation of the effect of omeprazole, a proton pump inhibitor, on the anti-platelet action of clopidogrel. The main decision criterion will concern change in VASP protein phosphorylation under treatment. Phosphorylation will be measured before and after administration of omeprazole versus placebo in patients undergoing clopidogrel treatment. Type of study: Single center, double blind, randomized parallel group study versus placebo, comparing two treatment groups: - clopidogrel + omeprazole + standard regime (beta-blockers, atorvastatin, IEC, aspirin) - clopidogrel + placebo+ standard regime (beta-blockers, atorvastatin, IEC, aspirin) Study population: 120 patients from the Cardiology Department of Brest University hospital, Brest (France), receiving a standard treatment comprising a loading dose of clopidogrel followed by a daily dose of 75 mg associated to 75 mg aspirin, will be randomized between 20 mg/day omeprazole and 20 mg/day placebo treatment groups. The efficacy of clopidogrel will be assessed by inter-group comparison on the VASP test. Study period: 7 days' treatment per patient. Total study period estimated at 6 months. Expected findings: The results should confirm the suspected negative effect of omeprazole on clopidogrel's impact on arterial thrombosis risk, secondarily allowing new recommendations to be drawn up for this association. |
NCT00441519 ↗ | A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin | Completed | POZEN | Phase 1 | 2007-02-01 | To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet |
NCT00442052 ↗ | To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin | Completed | POZEN | Phase 1 | 2006-11-01 | Primary: To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet combining 325 mg pH sensitive aspirin and 20 mg immediate release omeprazole versus a once-daily dose of 325 mg enteric coated aspirin utilizing Lanza scores from endoscopy findings in normal healthy volunteers. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Aspirin; Omeprazole
Condition Name
Clinical Trial Locations for Aspirin; Omeprazole
Trials by Country
Clinical Trial Progress for Aspirin; Omeprazole
Clinical Trial Phase
Clinical Trial Sponsors for Aspirin; Omeprazole
Sponsor Name